Finasteride
- Generic Name
- Finasteride
- Brand Names
- Entadfi, Propecia, Proscar
- Drug Type
- Small Molecule
- Chemical Formula
- C23H36N2O2
- CAS Number
- 98319-26-7
- Unique Ingredient Identifier
- 57GNO57U7G
- Background
Finasteride is a synthetic 4-azasteroid compound and specific inhibitor of steroid Type II 5α-reductase, which is an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT). It works in a similar fashion as dutasteride, which is another 5-alpha-reductase inhibitor, by exerting antiandrogenic effects. Finasteride is an ...
- Indication
Finasteride is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention, and reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. A combination product with tadalafil is also used...
- Associated Conditions
- Androgenetic Alopecia (AGA), Benign Prostatic Hyperplasia (BPH), Idiopathic Hirsutism, Symptomatic benign prostatic hyperplasia (BPH)
- Associated Therapies
- -
A Trial of PROSCAR (Finasteride) Versus Placebo in Men With an Initial Negative Prostate Biopsy
- First Posted Date
- 2007-10-11
- Last Posted Date
- 2015-12-09
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 19
- Registration Number
- NCT00542243
- Locations
- 🇨🇦
University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada
5-Alpha Reductase and Anabolic Effects of Testosterone
- Conditions
- Interventions
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 60
- Registration Number
- NCT00475501
- Locations
- 🇺🇸
North Florida/South Georgia Veterans Health System, Gainesville, Florida, United States
Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery
- Conditions
- Interventions
- First Posted Date
- 2007-02-22
- Last Posted Date
- 2016-03-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 204
- Registration Number
- NCT00438464
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸Cancer Therapy and Research Center, San Antonio, Texas, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
Kinetics of the Finasteride Prostate Induced Apoptosis
- Conditions
- First Posted Date
- 2005-08-16
- Last Posted Date
- 2007-04-27
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 90
- Registration Number
- NCT00130767
- Locations
- 🇫🇷
Centre hospitalier Lyon Sud, Pierre Bénite, France
Hormone Therapy in Treating Patients With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-08-13
- Last Posted Date
- 2016-07-04
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 101
- Registration Number
- NCT00003323
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
🇺🇸University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States
Medical Therapy of Prostatic Symptoms
- Conditions
- Interventions
- First Posted Date
- 2001-08-06
- Last Posted Date
- 2018-09-28
- Target Recruit Count
- 3407
- Registration Number
- NCT00021814
- Locations
- 🇺🇸
University of California, La Jolla, California, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
🇺🇸New York University School of Medicine, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.